INBX
Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$121.17
−0.89%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +22.3%
- EBIT
- +23.5%
- EPS
- +17.8%
- Free cash flow
- +5.9%
- Operating cash flow
- +5.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -11.5%
- EPS
- -10.1%
Three-year CAGR
- Revenue
- -16.0%
- EBITDA
- —
- EBIT
- +59.3%
- Net income
- —
- EPS
- —
- Free cash flow
- +34.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026